Relationship Between Prolonged Intraocular Inflammation and Macular Edema After Cataract Surgery.
Journal
Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
entrez:
14
6
2021
pubmed:
15
6
2021
medline:
29
6
2021
Statut:
ppublish
Résumé
To assess whether aqueous flare is related to an increased risk of pseudophakic cystoid macular edema (PCME) following uneventful cataract surgery in nondiabetic and diabetic patients. A post hoc analysis of five consecutive randomized clinical trials in the Department of Ophthalmology, Kymenlaakso Central Hospital, Finland. Aqueous flare levels were recorded in 448 eyes of 448 patients before surgery, and after the course of topical anti-inflammatory treatment 28 days and three months after cataract surgery. Aqueous flare increase of <50%, ≥50%, ≥100%, and ≥200% associated in central subfield macular thickness (CSMT) increase across the groups at 28 days and three months after surgery. Increase of aqueous flare ≥100% compared to those with <100% was associated with increased CSMT (P = 0.022 at 28 days, and P = 0.027 at three months). At three months, macular thickening (at least 10% CSMT increase) was observed in 12.7% compared to 4.6% of eyes when using a cutoff value of 100% increase in aqueous flare (P = 0.033). Although diabetic patients presented higher aqueous flare levels at baseline compared to nondiabetic patients (12.9 ± 11.8 vs. 9.8 ± 8.2 photon units/ms P < 0.001), the postoperative levels illustrated a similar profile in aqueous flare increase between the two groups. At 28 days, aqueous flare increase was associated with macular thickening. A 100% cutoff value could potentially be used when studying anti-inflammatory efficacy of different treatment protocols. Flare values exceeding this cutoff value could be considered as an indication for extending anti-inflammatory therapy. A 100% increase in aqueous flare at 28 days after cataract surgery from baseline predicted macular thickening up to three months postoperatively. Identifying a correlation between increased aqueous flare levels and pseudophakic cystoid macular edema may allow recognition of the most vulnerable patients, development of prophylactic treatment strategies and reduction of the number and severity of postoperative complications.
Identifiants
pubmed: 34125145
pii: 2772702
doi: 10.1167/tvst.10.7.15
pmc: PMC8212433
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
15Références
Ophthalmology. 2014 Oct;121(10):1915-24
pubmed: 24935281
BMC Ophthalmol. 2013 Dec 11;13:78
pubmed: 24325604
Acta Ophthalmol. 2019 Nov;97(7):688-694
pubmed: 30575287
J Cataract Refract Surg. 2018 Apr;44(4):429-439
pubmed: 29778106
Br J Ophthalmol. 2013 Apr;97(4):450-3
pubmed: 23355528
Acta Ophthalmol. 2011 Jun;89(4):369-75
pubmed: 19878107
Eur J Ophthalmol. 2019 Sep;29(5):504-509
pubmed: 30205708
Acta Ophthalmol. 2018 Dec;96(8):853-859
pubmed: 30284393
J Cataract Refract Surg. 1998 Aug;24(8):1099-104
pubmed: 9719970
J Ophthalmol. 2013;2013:376013
pubmed: 23738050
Int Ophthalmol. 2015 Oct;35(5):629-33
pubmed: 22855363
Int Ophthalmol. 2010 Oct;30(5):453-64
pubmed: 19430730
Retina. 2019 Dec;39(12):2283-2291
pubmed: 30312254
Ophthalmology. 2016 Feb;123(2):316-323
pubmed: 26681390
Acta Ophthalmol. 2016 Mar;94(2):e135-41
pubmed: 26408205
Br J Ophthalmol. 2013 Jul;97(7):862-5
pubmed: 23613514
Am J Ophthalmol. 2015 Nov;160(5):968-981.e33
pubmed: 26232601
Retina. 2016 Nov;36(11):2183-2190
pubmed: 27135211
Am J Ophthalmol. 2020 Jul;215:104-111
pubmed: 32061757
Acta Ophthalmol. 2018 Dec;96(8):e1043-e1044
pubmed: 30246338
Eur J Ophthalmol. 1999 Jul-Sep;9(3):158-64
pubmed: 10544971
Acta Ophthalmol. 2018 Mar;96(2):192-196
pubmed: 29068530
Ocul Immunol Inflamm. 2016;24(2):184-93
pubmed: 25541860
Arch Ophthalmol. 1995 Jul;113(7):867-9
pubmed: 7605276
J Cataract Refract Surg. 2017 Nov;43(11):1376-1382
pubmed: 29223225
Invest Ophthalmol Vis Sci. 2015 May;56(5):3407-14
pubmed: 26024125
Acta Ophthalmol. 2018 Aug;96(5):486-493
pubmed: 29369527
J Cataract Refract Surg. 2000 Mar;26(3):382-5
pubmed: 10713233
Br J Ophthalmol. 1994 Feb;78(2):91-4
pubmed: 8123632
Acta Ophthalmol. 2020 Feb;98(1):36-42
pubmed: 31210019
J Clin Med. 2020 Sep 21;9(9):
pubmed: 32967137
Acta Ophthalmol. 2019 Mar;97(2):178-184
pubmed: 30187630
J Cataract Refract Surg. 1997 Jul-Aug;23(6):935-9
pubmed: 9292681
Acta Ophthalmol Scand. 1998 Aug;76(4):413-6
pubmed: 9716326
Invest Ophthalmol Vis Sci. 1993 Oct;34(11):3124-30
pubmed: 8407220
Graefes Arch Clin Exp Ophthalmol. 2008 Aug;246(8):1169-77
pubmed: 18504599
Invest Ophthalmol Vis Sci. 1992 Feb;33(2):416-23
pubmed: 1740374
Br J Ophthalmol. 2017 Feb;101(2):180-185
pubmed: 27073207
Mol Vis. 2013 Nov 24;19:2418-25
pubmed: 24319335